SingapOre Lung Cancer Screening Through Integrating CT With Other biomarkErs (SOLSTICE)

NARecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Lung Cancer
Interventions
DIAGNOSTIC_TEST

Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays

"LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery."

Trial Locations (3)

168583

RECRUITING

National Cancer Centre, Singapore, Singapore

169608

RECRUITING

Singapore General Hospital, Singapore

169609

RECRUITING

National Heart Centre Singapore, Singapore

All Listed Sponsors
collaborator

Singapore General Hospital

OTHER

collaborator

National Heart Centre Singapore

OTHER

collaborator

Changi General Hospital

OTHER

collaborator

Sengkang General Hospital

OTHER

collaborator

Genome Institute of Singapore

OTHER

collaborator

National University of Singapore

OTHER

collaborator

Duke-NUS Graduate Medical School

OTHER

lead

National Cancer Centre, Singapore

OTHER